Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients

ABSTRACT Liposomal amphotericin B (LAMB) and caspofungin (CAS) are important antifungal agents in allogeneic hematopoietic stem cell transplant (aHSCT) recipients. Little is known, however, about the pharmacokinetics (PK) of both agents and their combination in this population. The PK of LAMB and CAS and the potential for PK interactions between both agents were investigated within a risk-stratified, randomized phase II clinical trial in 53 adult aHSCT recipients with granulocytopenia and refractory fever. Patients received either LAMB (n = 17; 3 mg/kg once a day [QD]), CAS (n = 19; 50 mg QD; day 1, 70 mg), or the combination of both (CAS-LAMB; n = 17) for a median duration of 10 to 13 days (range, 4 to 28 days) until defervescence and granulocyte recovery. PK sampling was performed on days 1 and 4. Drug concentrations in plasma (LAMB, 405 samples; CAS, 458 samples) were quantified by high-pressure liquid chromatography and were analyzed using population pharmacokinetic modeling. CAS concentration data best fitted a two-compartment model with a proportional error model and interindividual variability (IIV) for clearance (CL) and central volume of distribution (V1) (CL, 0.462 liter/h ± 25%; V1, 8.33 liters ± 29%; intercompartmental clearance [Q], 1.25 liters/h; peripheral volume of distribution [V2], 3.59 liters). Concentration data for LAMB best fitted a two-compartment model with a proportional error model and IIV for all parameters (CL, 1.22 liters/h ± 64%; V1, 19.2 liters ± 38%; Q, 2.18 liters/h ± 47%; V2, 52.8 liters ± 84%). Internal model validation showed predictability and robustness of both models. None of the covariates tested (LAMB or CAS comedication, gender, body weight, age, body surface area, serum bilirubin, and creatinine clearance) further improved the models. In summary, the disposition of LAMB and CAS was best described by two-compartment models. Drug exposures in aHSCT patients were comparable to those in other populations, and no PK interactions were observed between the two compounds.

[1]  J. Gerss,et al.  Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients , 2010, Antimicrobial Agents and Chemotherapy.

[2]  A. Groll,et al.  Recent advances in antifungal prevention and treatment. , 2009, Seminars in hematology.

[3]  B. Spellberg,et al.  Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  E. Bow.  Invasive Fungal Infection in Haematopoietic Stem Cell Transplant Recipients: Epidemiology from the Transplant Physician’s Viewpoint , 2009, Mycopathologia.

[5]  R. Goldberg,et al.  Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  R. Betts,et al.  Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  P. Deutsch,et al.  Single‐ and Multiple‐Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations , 2007, Journal of clinical pharmacology.

[8]  M. Weigand,et al.  Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. , 2007, The Journal of antimicrobial chemotherapy.

[9]  C. Heussel,et al.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Pittet,et al.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial , 2007, The Lancet.

[11]  A. Glasmacher,et al.  Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis , 2006, Cancer.

[12]  A. McLachlan,et al.  Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases , 2006, Antimicrobial Agents and Chemotherapy.

[13]  E. Niclas Jonsson,et al.  Erratum to "PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM" [Comput. Methods Prog. Biomedicine 79 (2005) 241-257] , 2005, Comput. Methods Programs Biomed..

[14]  A. Shad,et al.  Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents , 2005, Antimicrobial Agents and Chemotherapy.

[15]  E. Niclas Jonsson,et al.  PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..

[16]  S. Waldman,et al.  Potential for Interactions between Caspofungin and Nelfinavir or Rifampin , 2004, Antimicrobial Agents and Chemotherapy.

[17]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[18]  D. Reinhardt,et al.  Population pharmacokinetics of liposomal daunorubicin in children. , 2003, British journal of clinical pharmacology.

[19]  Russell E. Lewis,et al.  Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies , 2003, Cancer.

[20]  S. Gelone,et al.  Caspofungin Acetate for Treatment of Invasive Fungal Infections , 2003, The Annals of pharmacotherapy.

[21]  J. Perfect,et al.  Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.

[22]  T. Walsh,et al.  Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans , 2002, Antimicrobial Agents and Chemotherapy.

[23]  A. Sterrett,et al.  Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men , 2002, Antimicrobial Agents and Chemotherapy.

[24]  A. Groll,et al.  Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections , 2001, Expert opinion on investigational drugs.

[25]  W. Wilson,et al.  Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients , 1998, Antimicrobial Agents and Chemotherapy.

[26]  B. Matuszewski,et al.  Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection , 1997 .

[27]  Roger Kerouel,et al.  Assessment of heat treatment for nutrient preservation in seawater samples , 1997 .

[28]  W. Wilmanns,et al.  Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients , 1997, Antimicrobial agents and chemotherapy.

[29]  I. Bekersky,et al.  A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. , 1996, Therapeutic drug monitoring.

[30]  Nicholas H. G. Holford,et al.  A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.

[31]  Mosteller Rd.  Simplified Calculation of Body-Surface Area , 1987 .

[32]  R. O’rahilly,et al.  Book ReviewNeuroanatomy: An atlas of structures, sections and systems , 1987 .

[33]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[34]  Jos H. Beijnen,et al.  Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM , 2011, Comput. Methods Programs Biomed..

[35]  B. Thiers.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial , 2008 .

[36]  A. Boddy,et al.  The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion , 2004, Cancer Chemotherapy and Pharmacology.

[37]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[39]  S. Piscitelli,et al.  Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. , 1998, Advances in pharmacology.

[40]  R. Mosteller.  Simplified calculation of body-surface area. , 1987, The New England journal of medicine.